Recordati ISTURISA (Osilodrostat) LINC Program ENDO 2026 Data: Four Cushing's Syndrome Poster Presentations on Biochemical Control, Patient-Reported Quality of Life, and Real-World Outcomes
Recordati Rare Diseases presented four poster analyses at ENDO 2026 from the LINC clinical program for ISTURISA (osilodrostat), the oral 11β-hydroxylase inhibitor approved for Cushing's syndrome. The posters covered patient-reported quality-of-life improvements, biochemical control durability, real-world treatment outcomes across LINC 3 and LINC 4 study extensions, and clinical responses across the heterogeneous Cushing's syndrome population. ISTURISA was approved in March 2020 for Cushing's disease and expanded to broader Cushing's syndrome in April 2025; the LINC 3 pivotal study showed 86% of patients normalized urinary free cortisol after eight weeks of randomized withdrawal versus 29% with placebo. Endogenous Cushing's syndrome remains an ultra-rare endocrine disorder with limited therapeutic alternatives (ketoconazole, metyrapone, mifepristone, pasireotide).